|
|
Post by jlaw277 on Jan 13, 2020 12:25:31 GMT -5
Wondering if this is impacting the share price. United Therapeutics presenting jp Morgan Healthcare Conference Jan 13 @4:30PM ET ir.unither.com/events-presentationsHopefully a little more clarity for MNKD shareholders. |
|
|
|
Post by rravis1914 on Jan 13, 2020 12:38:27 GMT -5
Very Interesting!!!!!
I would like to think of this as a positive for long suffering longs.
|
|
|
|
Post by winner on Jan 13, 2020 12:44:10 GMT -5
Great find jlaw277. Fingers crossed.
|
|
|
|
Post by mango on Jan 13, 2020 12:46:09 GMT -5
Hasn’t started yet...
|
|
|
|
Post by sportsrancho on Jan 13, 2020 15:09:12 GMT -5
Stock moving up on anticipation. |
|
|
|
Post by mango on Jan 13, 2020 16:40:55 GMT -5
Nothing new concerning TreT in the slide deck. Have not listened to the presentation, however, nor the Q&A.
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Jan 13, 2020 17:08:42 GMT -5
Question about status of TreT in the Q&A.
complete clinical trial in May.
going on in parallel with production of trepostinel used in dreamboat. That product will complete its 12 month ? test and approved by end of 2021.
launch will be between 4th qtr 2021 and 1st half 2022.
|
|
|
|
Post by compound26 on Jan 13, 2020 17:09:17 GMT -5
Someone asked a question on this. Breeze trial enrollment expected to complete by May 2020. 12-month product stability test to complete by end of 2020. FDA submission is expected end of year 2020. Product (TreT) will probably be launched in the fourth quarter of 2021 or first half of 2022.
|
|
|
|
Post by goyocafe on Jan 13, 2020 17:11:38 GMT -5
Someone asked a question on this. It is said the product (TreT) will probably be launched in the fourth quarter of 2021 or first half of 2022. And this is after taking advantage of the shortened trial time frame based on prior statements. What was it? A safety trial and a shortened efficacy trial? I don't recall the specifics, but thought we would see this sooner. |
|
|
|
Post by mango on Jan 13, 2020 17:17:35 GMT -5
Someone asked a question on this. Breeze trial enrollment expected to complete by May 2020. 12-month product stability test to complete by end of 2020. FDA submission is expected end of year 2020. Product (TreT) will probably be launched in the fourth quarter of 2021 or first half of 2022. What is the details surrounding the product stability test? First I am hearing of it. |
|
|
|
Post by mango on Jan 13, 2020 17:21:26 GMT -5
Anything mentioned about the undisclosed molecule.
|
|
|
|
Post by Clement on Jan 13, 2020 17:30:15 GMT -5
Nothing about the undisclosed molecule
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Jan 13, 2020 18:11:00 GMT -5
It's after 6:00pm ET and the webcast recording status is still: "The live webcast has ended. We are currently preparing a recording of this session".
|
|
|
|
Post by brotherm1 on Jan 13, 2020 20:12:16 GMT -5
Someone asked a question on this. It is said the product (TreT) will probably be launched in the fourth quarter of 2021 or first half of 2022. And this is after taking advantage of the shortened trial time frame based on prior statements. What was it? A safety trial and a shortened efficacy trial? I don't recall the specifics, but thought we would see this sooner. 🥵. And the deceit continues. |
|
|
|
Post by boca1girl on Jan 13, 2020 20:22:43 GMT -5
Very disappointed in this schedule. No royalties for 2 - 2.5 years yet?
I thought TreT would be available early 2021. Boy was I wrong!
|
|
